- active not recruitingPHASE3
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
This study looks at the long-term safety and effects of a treatment called iptacopan for primary IgA Nephropathy, a kidney condition. It's for people who have already been in earlier studies for this medication and want to continue receiving it while more information is gathered.
United States · Argentina · Australia - recruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Sefaxersen (RO7434656) in Participants With Primary Immunoglobulin A (IgA) Nephropathy at High Risk of Progression
This study is testing a new medicine called sefaxersen for people with a kidney disease called IgA nephropathy. We want to see if it's safe and helps slow down kidney damage, especially for those at higher risk.
United States · Argentina · Australia